Literature DB >> 16423623

Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy.

Steen B Haugaard1, Ove Andersen, Steen B Pedersen, Flemming Dela, Mogens Fenger, Bjørn Richelsen, Sten Madsbad, Johan Iversen.   

Abstract

Tumor necrosis factor alpha (TNF-alpha) stimulates lipolysis in man. We examined whether plasma TNF-alpha is associated with the degree by which insulin suppresses markers of lipolysis, for example, plasma free fatty acid (FFA) and net lipid oxidation (LIPOX) rate in HIV-infected patients with lipodystrophy (LIPO) and those without (controls). LIPOX was estimated by indirect calorimetry during fasting and steady state of a hyperinsulinemic euglycemic clamp in 36 (18 LIPO and 18 controls) normoglycemic HIV-infected men on highly active antiretroviral therapy. In LIPO, TNF-alpha correlated with clamp FFA (r = 0.67, P < .01), clamp LIPOX (r = 0.47, P < .05), incremental FFA (r = 0.69, P < .01), and incremental LIPOX (r = 0.64, P < .01), all of which, but not the clamp LIPOX correlation (r = 0.29, P > .05), remained significant after correction for insulin sensitivity. None of these correlations were significant in controls. In all patients, TNF-alpha correlated with clamp FFA (r = 0.61, P < .001), clamp LIPOX (r = 0.43, P < .01), and incremental FFA (r = 0.43, P < .01), with the 2 former correlations remaining significant after correction for insulin sensitivity. LIPOX and FFA (fasting and clamp values combined) correlated strongly and positively in both LIPO (R2 = 0.43, P < .001) and controls (R2 = 0.60, P < .0001). Fasting FFA and LIPOX did not differ between study groups; however, the insulin-mediated suppression of FFA and LIPOX was attenuated in LIPO (P's < .05). Our data indicate that higher TNF-alpha, independently of insulin sensitivity, is associated with attenuated insulin-mediated suppression of FFA and LIPOX in HIV-LIPO, suggesting in turn that TNF-alpha stimulates lipolysis in this syndrome. Furthermore, FFA may be a major determinant of LIPOX in HIV-infected patients on highly active antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423623     DOI: 10.1016/j.metabol.2005.08.018

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  13 in total

Review 1.  Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection.

Authors:  Emily Bowman; Nicholas T Funderburg
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

2.  Effects of Weight Loss on Adipose and Muscular Neuropilin 1 mRNA Expression in Obesity: Potential Implication in SARS-CoV-2 Infections?

Authors:  Dominik Soll; Finja Beer; Leonard Spranger; Linna Li; Joachim Spranger; Knut Mai
Journal:  Obes Facts       Date:  2021-12-10       Impact factor: 3.942

Review 3.  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Authors:  Erdembileg Anuurad; Alison Semrad; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

4.  Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection.

Authors:  Larisa Dubrovsky; Rachel Van Duyne; Svetlana Senina; Irene Guendel; Tatiana Pushkarsky; Dmitri Sviridov; Fatah Kashanchi; Michael Bukrinsky
Journal:  Biochem Biophys Res Commun       Date:  2012-02-04       Impact factor: 3.575

5.  Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

Authors:  Jeroen P H van Wijk; Manuel Castro Cabezas
Journal:  Int J Vasc Med       Date:  2011-08-22

6.  Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.

Authors:  Asita Wongprikorn; Chonlaphat Sukasem; Apichaya Puangpetch; Pawin Numthavej; Ammarin Thakkinstian; Sasisopin Kiertiburanakul
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

Review 7.  Insulin Resistance in HIV-Patients: Causes and Consequences.

Authors:  Marcelo N Pedro; Guilherme Z Rocha; Dioze Guadagnini; Andrey Santos; Daniela O Magro; Heloisa B Assalin; Alexandre G Oliveira; Rogerio de Jesus Pedro; Mario J A Saad
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-05       Impact factor: 5.555

8.  Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction.

Authors:  Gerard Wong; Janine M Trevillyan; Benoit Fatou; Michelle Cinel; Jacquelyn M Weir; Jennifer F Hoy; Peter J Meikle
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

9.  Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria.

Authors:  Cajetan C Onyedum; Ekenechukwu E Young; Michael O Iroezindu; Chinwe J Chukwuka; Uchenna I Nwagha
Journal:  Indian J Endocrinol Metab       Date:  2014-09

10.  Diabetes mellitus among HIV-infected individuals in follow-up care at University of Gondar Hospital, Northwest Ethiopia.

Authors:  Solomon Mekonnen Abebe; Assefa Getachew; Solomon Fasika; Mulugeta Bayisa; Abayneh Girma Demisse; Nebiyu Mesfin
Journal:  BMJ Open       Date:  2016-08-18       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.